Systemic Administration of α7-Nicotinic Acetylcholine Receptor Ligands Does Not Improve Renal Injury or Behavior in Mice With Advanced Systemic Lupus Erythematosus
Open Access
- 13 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
Abstract
There is a critical need for safe treatment options to control inflammation in patients with systemic lupus erythematosus (SLE) since the inflammation contributes to morbidity and mortality in advanced disease. Endogenous neuroimmune mechanisms like the cholinergic anti-inflammatory pathway can be targeted to modulate inflammation, but the ability to manipulate such pathways and reduce inflammation and end organ damage has not been fully explored in SLE. Positive allosteric modulators (PAM) are pharmacological agents that inhibit desensitization of the nicotinic acetylcholine receptor (α7-nAChR), the main anti-inflammatory feature within the cholinergic anti-inflammatory pathway, and may augment α7-dependent cholinergic tone to generate therapeutic benefits in SLE. In the current study, we hypothesize that activating the cholinergic anti-inflammatory pathway at the level of the α7-nAChR with systemic administration of a partial agonist, GTS-21, and a PAM, PNU-120596, would reduce inflammation, eliminating the associated end organ damage in a mouse model of SLE with advanced disease. Further, we hypothesize that systemic α7 ligands will have central effects and improve behavioral deficits in SLE mice. Female control (NZW) and SLE mice (NZBWF1) were administered GTS-21 or PNU-120596 subcutaneously via minipumps for 2 weeks. We found that the increased plasma dsDNA autoantibodies, splenic and renal inflammation, renal injury and hypertension usually observed in SLE mice with advanced disease at 35 weeks of age were not altered by GTS-21 or PNU-120596. The anxiety-like behavior presented in SLE mice was also not improved by GTS-21 or PNU-120596. Although no significant beneficial effects of α7 ligands were observed in SLE mice at this advanced stage, we predict that targeting this receptor earlier in the pathogenesis of the disease may prove to be efficacious and should be addressed in future studies.Funding Information
- Lupus Research Alliance
- National Institutes of Health
This publication has 68 references indexed in Scilit:
- A Type-II Positive Allosteric Modulator of α7 nAChRs Reduces Brain Injury and Improves Neurological Function after Focal Cerebral Ischemia in RatsPLOS ONE, 2013
- Downregulation of alpha7 nicotinic acetylcholine receptor in two-kidney one-clip hypertensive ratsBMC Cardiovascular Disorders, 2012
- Oxidative Stress Promotes Hypertension and Albuminuria During the Autoimmune Disease Systemic Lupus ErythematosusHypertension, 2012
- Blood pressure in a hypertensive mouse model of SLE is not salt-sensitiveAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Murine Models of Systemic Lupus ErythematosusJournal of Biomedicine and Biotechnology, 2011
- T cells as therapeutic targets in SLENature Reviews Rheumatology, 2010
- Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemiaProceedings of the National Academy of Sciences of the United States of America, 2008
- Nicotine Protects Kidney from Renal Ischemia/Reperfusion Injury through the Cholinergic Anti-Inflammatory PathwayPLOS ONE, 2007
- Physiology and immunology of the cholinergic antiinflammatory pathwayJCI Insight, 2007
- Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammationNature, 2002